- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Revelation Biosciences, Inc.: Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology | 201 | ACCESS Newswire | - Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the... ► Artikel lesen | |
| 12.01. | Revelation Biosciences, Inc.: Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 210 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen | |
| 07.01. | Revelation Biosciences begins GMP manufacturing for GEMINI trials | 1 | Investing.com | ||
| 07.01. | Revelation Biosciences startet GMP-Produktion für klinische Studien zu GEMINI | 4 | Investing.com Deutsch | ||
| 07.01. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development | 117 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen | |
| 03.12.25 | Aktionäre von Revelation Biosciences stimmen Ausgabe von Stammaktien für Optionsscheine zu | 3 | Investing.com Deutsch | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03.12.25 | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.12.25 | Revelation Biosciences, Inc.: Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting | 180 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing... ► Artikel lesen | |
| 20.11.25 | Revelation Biosciences, Inc.: Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year | 229 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen | |
| 12.11.25 | REVELATION BIOSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 06.11.25 | Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 | 320 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen | |
| 29.10.25 | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.10.25 | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date | 195 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 15.10.25 | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.10.25 | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 | 378 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 16.09.25 | Revelation Biosciences files to sell 13.07M shares of common stock by selling shareholders | 4 | Seeking Alpha | ||
| 11.09.25 | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds | 382 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 10.09.25 | Revelation Biosciences: Wirkstoffkandidat Gemini zeigt vielversprechende Ergebnisse bei chronischer Nierenerkrankung | 2 | Investing.com Deutsch | ||
| 10.09.25 | Revelation Biosciences, Inc.: Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data | 392 | ACCESS Newswire | - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data... ► Artikel lesen | |
| 09.09.25 | Revelation Biosciences, Inc.: Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data | 310 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 317,25 | +6,55 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,14 | -3,41 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 72,51 | -0,12 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 88,64 | +4,26 % | Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why | ||
| ADMA BIOLOGICS | 17,310 | -1,09 % | ADMA Biologics, Inc. (ADMA): A Bull Case Theory | ||
| BEAM THERAPEUTICS | 31,220 | -2,59 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| ERASCA | 9,625 | +0,68 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| CG ONCOLOGY | 54,73 | +3,13 % | CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why | ||
| JANUX THERAPEUTICS | 13,760 | +0,29 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TANGO THERAPEUTICS | 13,010 | +11,29 % | Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data | ||
| IMMUNOME | 22,410 | -1,93 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| QIAGEN | 39,255 | -3,83 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 10,160 | -3,24 % | Day One Biopharmaceuticals stock initiated with Buy rating at TD Cowen | ||
| AMYLYX PHARMACEUTICALS | 14,300 | +5,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,350 | -3,67 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen |
Das Unternehmen REVELATION BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +4,93 % bei einem Aktienkurs von 0,949 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.